---
title: "Oppenheimer maintains Outperform rating on Amgen, $480 price target"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/302912636.md"
description: "Oppenheimer maintains an Outperform rating on Amgen with a $480 price target, implying 7.3% upside from the Oct 22 close. The firm cites Amgen's robust R&D pipeline in oncology and rare diseases for long-term revenue growth, alongside financial discipline expected to expand operating margins. A ~3% dividend yield provides additional valuation support."
datetime: "2026-10-23T17:03:29.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/302912636.md)
  - [en](https://longbridge.com/en/news/302912636.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/302912636.md)
generator: "portal-rs"
---

# Oppenheimer maintains Outperform rating on Amgen, $480 price target

Oppenheimer maintained their Outperform rating on Amgen's stock with a price target of $480.00.

The price target implies an upside of 7.3% from the Oct 22 close of $447.28.

**Key takeaways from the analyst note**

**Strong Pipeline and Revenue Growth**: Amgen is expected to achieve long-term revenue growth driven by its robust R&D pipeline, which is poised to compensate for the decline of mature products. The anticipated launch of new innovative therapies, particularly in oncology and rare diseases, will enhance Amgen's market position and financial performance.

**Financial Discipline and Dividend Support**: The company has a proven track record of financial discipline, which is expected to lead to operating margin expansion. Additionally, Amgen offers a dividend yield of approximately 3%, providing valuation support and making it an attractive investment for shareholders seeking income alongside growth potential.

Explore more price target data and ratings for Amgen on the .

**Disclaimer**

Select reference data provided by Benzinga. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [AMGN.US](https://longbridge.com/en/quote/AMGN.US.md)
- [OPY.US](https://longbridge.com/en/quote/OPY.US.md)

## Related News & Research

- [Amgen Inc. $AMGN Shares Acquired by VestGen Advisors LLC](https://longbridge.com/en/news/303720186.md)
- [Amgen Says Imdelltra Combo Reduced Risk Of Death By 58% In First-Line Lung Cancer](https://longbridge.com/en/news/302966836.md)
- [FDA warns Amgen over cancer drug promotional video](https://longbridge.com/en/news/303273297.md)
- [AMGN: DeLLphi-305 showed a significant survival benefit for first-line maintenance IMDELLTRA plus IMFINZI](https://longbridge.com/en/news/302970188.md)
- [Amgen, AstraZeneca Drug Combo Shows Promising Survival Results in Tough-To-Treat Lung Cancer](https://longbridge.com/en/news/303091953.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**